Search
Trihexyphenidyl
go.drugbank.com/drugs/DB00376ApprovedInvestigational[L31773,L31778] Its discovery was published in 1949 in a study looking for drugs with antispasmodic activity. … [L31843] Trihexyphenidyl was granted FDA approval on 13 May 1949.[L31768]
International brands: Ea TenFostamatinib
go.drugbank.com/drugs/DB12010ApprovedInvestigationalIt was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, L52150]. Fostamatinib has also been granted orphan drug status by the FDA [L2644]. … Recently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modulate the SYK
Maralixibat
go.drugbank.com/drugs/DB16226ApprovedInvestigationalwith Alagille syndrome:[L43547] it was granted marketing authorization in Europe on 13 December 2022. … [A239249] Maralixibat represents the first FDA-approved treatment for cholestatic pruritus in patients with Alagille syndrome. It was granted FDA approval on 29 September 2021.
mRNA-1345
go.drugbank.com/drugs/DB18739ApprovedInvestigationalmRESVIA was first approved in the EU and US in 2024 for use in patients 60 years of age and older. … [L53403,L53393] It is additionally under investigation for maternal use and use in children.[A274028,L53438,L53443]
Idursulfase
go.drugbank.com/drugs/DB01271ApprovedInvestigationalIdursulfase is produced by recombinant DNA technology in a human cell line. … Idursulfase is an enzyme that hydrolyzes the 2-sulfate esters of terminal iduronate sulfate residues from the glycosaminoglycans dermatan sulfate and heparan sulfate in the lysosomes of various cell types
Polidocanol
go.drugbank.com/drugs/DB06811ApprovedInvestigationalPolidocanol is a sclerosing agent indicated to treat uncomplicated spider veins (varicose veins ≤1 mm in diameter) and uncomplicated reticular veins (varicose veins 1 to 3 mm in diameter) in the lower … The formula for Polidocanol has the structural formula C12H25(OCH2CH2)nOH, a mean extent of polymerization (n) of approximately 9 and a mean molecular weight of approximately 600.
Categories: Compounds used in a research, industrial, or household settingLecanemab
go.drugbank.com/drugs/DB14580ApprovedInvestigational[A253962,L44547] On January 6, 2023, lecanemab was granted accelerated approval by the FDA for the treatment of Alzheimer’s Disease.[L44547] It was granted full FDA approval on July 6, 2023. … [A253947,A253957] In clinical trials, it significantly reduced brain Aβ plaques compared to placebo.
Durvalumab
go.drugbank.com/drugs/DB11714ApprovedInvestigationalsmall cell lung cancer (ES-SCLC). … [L12621] In September 2018, durvalumab was approved by the EMA for the treatment of adult patients with locally advanced, unresectable non-small cell lung cancer (NSCLC), only if PD-L1 is expressed in
Avatrombopag
go.drugbank.com/drugs/DB11995ApprovedInvestigational[F95] Avatrombopag was first approved by the FDA in May 2018 for use in adults with chronic liver disease who are scheduled to undergo a procedure. … Avatrombopag (_Doptelet_), is an orally administered, small molecule thrombopoietin receptor (c-Mpl) agonist that increases platelet number without increasing platelet activation,[A33097,L2824] thereby
Methyldopa
go.drugbank.com/drugs/DB00968ApprovedInvestigational[A232224] First introduced in 1960 as an antihypertensive agent, methyldopa was considered to be useful in certain patient populations, such as pregnant women and patients with renal insufficiency. … [A231784] It is an analog of DOPA (3,4‐hydroxyphenylanine), and it is a prodrug, meaning that the drug requires biotransformation to an active metabolite for therapeutic effects.